Can Fite Biopharma Ltd ADR (CANF NYSE MKT) stock market data APIs
$1.0192
0(0%)
as of July 3, 2025
Try our APIs with
free plan!
Can Fite Biopharma Ltd ADR Financial Data Overview
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Prev. Close
1.0192
Open
1.0192
High
1.0397
Low
1.0192
52 wk Range
0.98-4.69
Market Cap
13 135 K
P/E Ratio
0
Shares Outstanding
12 877 K
Revenue
674 K
EPS
0
Beta
0.231
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Can Fite Biopharma Ltd ADR data using free add-ons & libraries
Get Can Fite Biopharma Ltd ADR Fundamental Data
{
"General": {
"Code": "CANF",
"Type": "Common Stock",
"Name": "Can Fite Biopharma Ltd ADR",
"Exchange": "NYSE MKT",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG003CMFDM2",
"ISIN": null,
"CUSIP": null,
"CIK": "0001536196",
"EmployerIdNumber": "",
"FiscalYearEnd": "December",
"IPODate": "2012-11-06",
"InternationalDomestic": "International\/Domestic",
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": "ADR",
"IsDelisted": false,
"Description": "Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed..."
}
}Can Fite Biopharma Ltd ADR Fundamental data includes:
- Net Revenue: 674 K
- EBITDA: -8 123 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-14
- EPS/Forecast: -0.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Can Fite Biopharma Ltd ADR News
New
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
PETACH TIKVA, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Shares of Minerva Neurosciences NERV were down 38.9% on Dec 28 after management announced that the FDA’s refuse-to-file letter on the company’s new drug application (“NDA”) filing was still in...
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
Pacira BioSciences, Inc. PCRX reported third-quarter 2022 adjusted earnings of 64 cents per share, missing the Zacks Consensus Estimate of 73 cents. The company reported adjusted earnings of 72 cents ...
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
Corcept Therapeutics Incorporated CORT reported earnings of 30 cents per share for third-quarter 2022, beating the Zacks Consensus Estimate of 23 cents. In the year-ago quarter, the company reported e...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
